# T1d Islet Autoantibody Screening Confirmation > Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569). - Skill: `dromlakhani/t1d-islet-autoantibody-screening-confirmation` (Agent Skill) - Install (CLI): `npx skillmds@latest add dromlakhani/t1d-islet-autoantibody-screening-confirmation` - Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/t1d-islet-autoantibody-screening-confirmation/raw - Safety review: pending (external: skill-scanner PASS, skillspector PASS) - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: dromlakhani (https://skillmd.com/u/dromlakhani) - Updated: 2026-09-08 - Page: https://skillmd.com/skills/dromlakhani/t1d-islet-autoantibody-screening-confirmation --- # T1D Islet Autoantibody Screening & Confirmation Detect and confirm islet autoimmunity for early-stage T1D. Every positive screen MUST be confirmed before staging or clinical action. --- ## Step 1 — Decide who to screen The IDF Europe consensus supports **general population screening** for islet autoantibodies as the way to detect early-stage T1D (Stages 1 and 2). Rationale: >85% of new T1D diagnoses have no family history — family-history-only screening misses most cases. **Screening candidates:** | Group | Screening indication | |---|---| | **General paediatric population** (approx 1–17 y) | Yes — where public health programs exist. Ongoing European programs (Fr1da, ELSA, EDENT1FI, D1Ce, βetty, RADAR1, SCREEND1A) enrol children in this age range | | **First-degree relatives** of a person with T1D | Yes — well-established indication; higher prior probability | | **General adult population** | Emerging indication (UNISCREEN Italy, T1DRA UK). At least 50% of new T1D is in adults, so this gap matters | | **Genetically at-risk newborns** (e.g. HLA-DR3/DR4) | Enrolled in monitoring studies (GPPAD, DIPP, BABYDIAB) — not routine screening | | **Newborn universal islet-autoantibody screening** | Not useful — antibodies at birth are largely maternal transmission, not the infant's own | --- ## Step 2 — Order the four islet autoantibodies **Test all four in the same sample:** 1. **GAD65** — glutamic acid decarboxylase (islet cell auto-antigen) 2. **IAA** — insulin autoantibodies (only informative BEFORE any insulin exposure; positive result becomes uninterpretable after exogenous insulin) 3. **IA2** — islet antigen 2 (tyrosine phosphatase-related) 4. **ZnT8** — zinc transporter 8 Reason for testing all four: the number of positive autoantibodies drives staging (single positive = At Risk; ≥2 = Stage 1 or beyond) and monitoring intensity. Testing fewer risks understaging. **Sample type — either is acceptable:** - **Venous serum** — traditional, higher sensitivity, requires clinic/lab visit - **Capillary sample / dried blood spot (DBS)** — validated for the 3-Screen ICA ELISA (Fr1da study) and radiobinding-microassay (ASK study); enables at-home / community collection. **Preferred by ~90% of screened participants** (UNISCREEN feasibility data) - **Fingerstick capillary** — used in UNISCREEN pilot with 90% technical success rate **Assay method:** - Radiobinding assay (RBA) — historically the reference standard - ELISA — used in modern screening programs (e.g. 3-Screen ICA) - Electrochemiluminescence — increasingly used Different programs use different primary assays. What matters for confirmation is that the second sample uses a **different method** from the first (see Step 4). --- ## Step 3 — Interpret the first-round result Three possible outcomes: **A. All four antibodies negative** - >99% of general population screens fall here - No further action required this round - Educate the person that a negative screen is not a lifetime guarantee — routine future screening is still relevant - If asymptomatic → discharge from monitoring - Communicate results with clarity to reduce anxiety about repeated future screens **B. One antibody positive (single positive)** - **Do NOT stage yet** — proceed to Step 4 confirmation - Interpret carefully — a single unconfirmed positive is often a false positive - If confirmed on second sample with 2 methods → **At Risk** category (~10–15% progression to Stage 3 over 15 years vs 0.3% general population) **C. Two or more antibodies positive (multi-positive)** - **Do NOT skip Step 4 confirmation** even though multi-positivity has a much higher pre-test probability of being real - Confirmation is still standard practice; false-positive combinations do occur --- ## Step 4 — Mandatory confirmation protocol **For ANY positive screen (single or multiple), confirm with:** 1. **A second, separate sample** — drawn on a different day (do not re-run the same sample). Sample can be capillary or venous 2. **Two independent laboratory methods** applied to the confirmatory sample — e.g. if the initial screen used ELISA, the confirmation should include a radiobinding or electrochemiluminescence method 3. **Test for ALL four antibodies again**, not just the ones that were positive first time 4. **Confirm negative status for the other three** (i.e. explicitly document that only the reported antibodies are positive) **Confirmed positive** = same antibody(ies) positive on second sample AND on two independent methods. **Discordant result** (positive on first sample, negative on second, or positive on one method but not the other) = treat as **transient / At Risk**. Repeat the full panel in 6–12 months. --- ## Step 5 — Interpret the confirmed result and route | Confirmation outcome | Route to | |---|---| | **All negative on confirmation** (initial positive was false) | Reassure. Retest per screening program cadence | | **Confirmed single autoantibody positive** | **At Risk** — see `t1d-staging-classifier`. Retesting every 12 months, symptom education, no monitoring program required | | **Confirmed ≥2 autoantibodies positive** | **Stage 1 or higher** — proceed to full glycaemic staging (FPG, OGTT, HbA1c, CGM if available) via `t1d-staging-classifier`. Enrol in monitoring program | | **Transient single positive** (positive → negative on repeat) | At Risk. Repeat testing in 6–12 months. Do NOT stage as Stage 1 | --- ## Step 6 — Post-screen communication and psychosocial support **Immediate post-screen actions (regardless of result):** - **Clear written and verbal explanation** of what the result means and does not mean - **Symptom education** — signs of Stage 3 T1D (polyuria, polydipsia, weight loss, DKA warning signs) - **Emergency contact route** if osmotic symptoms develop **Additional actions for positive confirmed screens:** - **Psychological support** — anxiety and distress are common (up to 30% of parents report worry that persists). Anticipate this and offer proactively - **Peer support** — sharing experience with other families in the same situation improves adjustment (preliminary evidence) - **Enrol in structured monitoring program** — the ONLY way early-stage T1D detection reduces DKA is via active monitoring, not screening alone - **Discuss disease-modifying therapy (teplizumab)** if Stage 2 is confirmed — see `teplizumab-eligibility-and-course` --- ## Guardrails - **A single unconfirmed positive is not a diagnosis** — never communicate "your child has early T1D" on the basis of one positive screen. Wait for the second-sample + two-method confirmation - **Test all four antibodies** every time — testing GAD alone or IA2 alone misses the multi-antibody information that drives staging - **IAA becomes uninterpretable after any insulin exposure** — schedule the sample BEFORE any insulin. If the person has already received insulin (e.g. in DKA workup), IAA cannot be used and the panel is effectively three-antibody - **Confirmation must use a DIFFERENT method** from the initial screen, not the same method twice - **Capillary/DBS sampling is legitimate** — do not force venepuncture if a validated at-home DBS kit is available; participation drops otherwise - **Screening is not a one-off event** — a negative screen at age 5 does not exclude later development. Communicate this clearly to avoid false reassurance - **Positive results in the absence of symptoms are OFTEN not celebrated** — the family may feel worry, guilt, or grief. Prepare the psychosocial team before results are given - **Do not use islet autoantibody screening to differentiate types of ALREADY-diagnosed diabetes** unless combined with clinical judgement — GAD antibodies can be positive in a subset of adult-onset diabetes that overlaps with LADA/T2DM. That is a different clinical question from general population screening for early T1D - **Do not screen newborns with universal islet autoantibody panels** — antibodies at birth are largely maternal transmission. Newborn screening is for HLA/genetic risk (research context), not autoantibodies - **Every positive confirmed screen MUST be paired with an enrolment pathway** — otherwise the screening program produces anxiety without benefit - **Document assay names and reference ranges** in the record — assays and cut-offs vary across labs and change over time; later interpretation depends on knowing what was used --- ## Related MD2SKILL skills - `t1d-staging-classifier` — after confirmed positive, assign the stage - `teplizumab-eligibility-and-course` — for confirmed Stage 2 T1D - `nd-t2d-oad-selector` — if working up an adult with new hyperglycaemia and the antibody result changes the type --- ## Source Hussain S, Tree T, Mathieu C, Klupa T, Tuomaala A-K, de Wit M, Kordonouri O, Braune K, Pall J, Castano L, Besser REJ, Galhardo J, Ulivi F, Bosi E, Bogdanovic U, Alabert C, Battelino T. **An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.** *Diabetes, Obesity and Metabolism.* 2026;28:3535–3556. DOI: 10.1111/dom.70569. Open-access under Creative Commons Attribution (CC-BY). Sections 3, 6, 7, 8, 11, 12, 13, and Recommendations.